FDA delays verdict on Beren’s rare disease drug by three months

FDA Extends Review for Beren's Niemann-Pick Disease Drug

The FDA has extended its decision date for Beren Therapeutics’ intrathecal injection, adrabetadex, for infantile-onset Niemann-Pick disease type C. Initially set for August 17, the new target action date is November 17. This three-month delay was prompted by Beren's submission of additional data and documentation in March, which the agency deemed a major adjustment to the original drug application, necessitating an extension of the review period.

• The FDA's decision to extend the review period for adrabetadex stems from Beren Therapeutics' submission of additional data and documentation in March. This submission was in response to a previous FDA request and was considered a major amendment to the original drug application, triggering the need for more time for the agency's comprehensive review.
• Adrabetadex is a proprietary mixture of various isomers of the oligomer 2-hydroxypropyl-β-cyclodextrin, designed to restore cholesterol trafficking in cells. It is specifically proposed for infantile-onset Niemann-Pick disease type C (NPC), a severe neurodegenerative disorder affecting children younger than six years, characterized by rapid progression and poor prognosis due to NPC1 or NPC2 gene mutations.
• Beren's adrabetadex previously received Breakthrough Therapy designation from the FDA in December last year, following data showing a 71% reduction in the risk of death versus external controls. If approved, it will enter a market that already includes Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa, with Azafaros also advancing its NPC therapy, nizubaglustat, in late-stage development.

Addressing Unmet Needs in Infantile-Onset Niemann-Pick Disease Type C

Recent research has identified significant gaps in Niemann-Pick disease type C management, particularly around treatment efficacy and disease progression. Current therapeutic approaches, while showing promise, remain insufficient to fully address the progressive neurological deterioration characteristic of this rare lysosomal storage disorder. Clinical development efforts are focusing on specific patient populations and novel therapeutic mechanisms to overcome existing limitations.

• Treatment efficacy limitations - Current treatments are not highly effective, with patients experiencing continued disease progression despite therapy with miglustat and other approved agents, necessitating development of more potent disease-modifying therapies

• Pediatric and early-onset populations - Clinical trials are targeting patients aged ≥4 years with established NPC diagnosis, including studies in Chinese populations (median age 14.0 years) and broader age ranges (5-67 years), with emphasis on early intervention to preserve neurological function

• Blood-brain barrier penetration challenges - Subcutaneous delivery of therapeutic agents like HP-γ-CD shows negligible improvement in neurological characteristics due to limited CNS penetration, driving development of alternative delivery methods including intracerebroventricular approaches

• Adverse event profiles - Current investigational treatments such as 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) present problematic safety concerns, requiring development of better-tolerated alternatives with improved biocompatibility

• Heterozygous carrier populations - Emerging evidence suggests carriers of single NPC gene variants may exhibit clinically relevant phenotypic traits attributable to partial NPC1 or NPC2 function loss, representing a previously unrecognized target population for monitoring and potential intervention

• Novel therapeutic mechanisms - Research is exploring CRISPR/Cas9 genome editing for disease modeling and gene therapy, calcium homeostasis modulation, and pharmacological chaperone approaches using antifungal agents to stabilize misfolded NPC1 proteins

• Disease-modifying versus symptomatic treatments - Current therapies primarily focus on symptom management rather than addressing underlying disease mechanisms, with N-acetyl-l-leucine showing promise as a disease-modifying agent with 118% reduction in annual disease progression

Adrabetadex's Position in the Evolving NPC Treatment Landscape

The Niemann-Pick disease type C treatment landscape has undergone significant development over the past five years, though no disease-modifying therapy has received FDA approval as of 2024, leaving treatment primarily supportive. The most substantial progress has centered on cyclodextrin-based therapeutics, with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD/HPBCD) emerging as the leading investigational treatment. This biocompatible cholesterol solubilizer has advanced through clinical trials and compassionate use programs, demonstrating efficacy in normalizing disrupted cholesterol homeostasis in NPC patient-derived cells and model systems. However, therapeutic doses have produced concerning adverse effects, including lung damage and ototoxicity, highlighting the need for improved formulations.

The cyclodextrin therapeutic class has expanded with the development of alternative derivatives designed to address safety limitations. 2-Hydroxypropyl-γ-cyclodextrin (HPGCD) has emerged as a promising candidate, offering a wider safety margin regarding ototoxicity and pulmonary toxicity compared to HP-β-CD while maintaining cholesterol-normalizing activity through a distinct interaction mechanism. Additionally, mono-6-O-α-maltosyl-γ-CD (G2-γ-CD) has shown preclinical promise as a fine-tuned cholesterol solubilizer with reduced ototoxicity in murine models, representing potential next-generation cyclodextrin therapeutics with improved therapeutic windows.

Beyond cyclodextrin approaches, the treatment pipeline has diversified to include gene therapy initiatives using AAV vectors, which are entering clinical trial planning phases, and continued development of miglustat (Zavesca), an iminosugar with α-glucosidase inhibitory activity. Importantly, the field has advanced in biomarker identification, with multiple pharmacodynamic endpoints now available to support clinical trials, including calbindin D, neurofilament light chain, various cholesterol metabolites, and neurodegeneration markers. However, correlation between these biomarkers and disease severity, progression, or treatment response remains unclear, representing a critical gap in the evolving treatment landscape.

Cyclodextrin's NPC Promise: FDA Extends Review, Signaling Deeper Scrutiny

The recent FDA decision to extend the review period for Beren Therapeutics’ adrabetadex, an intrathecal injection for infantile-onset Niemann-Pick disease type C (NPC), casts a spotlight on the intricate path of drug development for rare, devastating conditions. NPC is a fatal neurovisceral disorder with no approved treatments, making adrabetadex a beacon of hope for patients and families. The drug leverages 2-hydroxypropyl-β-cyclodextrin (HPβCD), a compound typically known for its role in enhancing drug solubility and bioavailability. However, in NPC, HPβCD has demonstrated direct therapeutic potential, slowing disease progression and reducing lipid accumulation in preclinical and early clinical studies.

This three-month delay, triggered by the submission of additional data, signals a thorough and cautious regulatory approach. For a potential first-in-class therapy targeting a severe pediatric population, the FDA's scrutiny is paramount. It suggests the agency is meticulously evaluating the comprehensive data package, which could include long-term safety, efficacy, and the nuances of intrathecal administration—a route critical for addressing the neurological manifestations of NPC. While intrathecal delivery has shown promise in other CNS disorders, its application here requires robust evidence.

However, this extended review also brings inherent risks. The known adverse effects of HPβCD, such as ototoxicity, are a significant concern, particularly for chronic use in children. The additional data may be crucial in addressing these safety profiles or clarifying the drug's complex mechanism of action, as research indicates HPβCD's efficacy might stem from enhanced pharmacokinetics rather than direct protein interaction. Furthermore, the regulatory history of other cyclodextrin-based drugs, like sugammadex, which initially faced a 'not-approvable' letter, underscores the potential for stringent review. This delay, while potentially leading to a stronger approval, prolongs the wait for patients and extends the period of market uncertainty for Beren Therapeutics, allowing more time for potential competitors to advance their own pipelines in the lysosomal storage disease space. The ultimate decision will not only shape the future of NPC treatment but also influence the broader development landscape for cyclodextrin-based therapies.